Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

As of June 30, 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H carries a market capitalization of 101.72B, placing it among publicly traded companies globally. Its enterprise value stands at 96.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H's next confirmed earnings release is scheduled for March 29, 2027.

As of June 30, 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 233.19M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H maintains a current ratio of 6.34, meaning it holds 6.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 23, 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H's stock has gained approximately 7.82% over the past 52 weeks. The 50-day moving average sits at 483.53, while the 200-day moving average is 457.55.

As of June 30, 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H holds 5.52B in cash and equivalents against 94.03M in total debt, resulting in a net debt position of -3.20B. Total book value stands at 6.17B, with working capital of 5.37B providing operational flexibility.